Literature DB >> 30901292

Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.

Yanheng Wu1, Wenyi Gu1, Jiang Li2, Chen Chen3, Zhi Ping Xu1.   

Abstract

AIM: To determine if silencing PD-1 on tumor-infiltrating lymphocytes (TILs) and its ligand-1 (PD-L1) on cancer cells will enhance the cytotoxicity of TILs. MATERIALS &
METHODS: Lipid-coated calcium phosphate nanoparticles were synthesized to deliver siRNAs against PD-1 and PD-L1 to TILs and breast cancer MCF-7 cells. The downregulation of PD-1/PD-L1 expressions was determined by real-time PCR and western blotting assays. The killing efficacy of TILs to MCF-7 cells was determined by cytotoxic T lymphocyte assay.
RESULTS: Lipid-coated calcium phosphate nanoparticles effectively delivered siRNAs and silenced PD-1 and PD-L1sh expression. The knockdown of either gene or both greatly improved the cytotoxicity of TILs.
CONCLUSION: Silencing PD-1 and PD-L1 is an effective approach to increase TIL cytotoxicity to cancer cells.

Entities:  

Keywords:  MCF-7; PD-1; PD-L1; TILs; breast cancer; cytokines; nanoparticles delivery; siRNA

Mesh:

Substances:

Year:  2019        PMID: 30901292     DOI: 10.2217/nnm-2018-0237

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  13 in total

Review 1.  The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.

Authors:  Yongjiang Li; Ciceron Ayala-Orozco; Pradipta Ranjan Rauta; Sunil Krishnan
Journal:  Nanoscale       Date:  2019-09-18       Impact factor: 7.790

Review 2.  siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion.

Authors:  Worapol Ngamcherdtrakul; Wassana Yantasee
Journal:  Transl Res       Date:  2019-08-19       Impact factor: 7.012

Review 3.  Nanomedicines in B cell-targeting therapies.

Authors:  Jiawei Wang; Jiyuan Yang; Jindřich Kopeček
Journal:  Acta Biomater       Date:  2021-10-21       Impact factor: 8.947

Review 4.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

5.  PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles Downregulate PD-1 Expression by Macrophages and Inhibit Tumor Growth : PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles.

Authors:  Mahmoud S Hanafy; Stephanie Hufnagel; Andrea N Trementozzi; Wedad Sakran; Jeanne C Stachowiak; John J Koleng; Zhengrong Cui
Journal:  AAPS PharmSciTech       Date:  2021-01-31       Impact factor: 3.246

6.  Electrotransfer of siRNA to Silence Enhanced Green Fluorescent Protein in Tumor Mediated by a High Intensity Pulsed Electromagnetic Field.

Authors:  Simona Kranjc Brezar; Matej Kranjc; Maja Čemažar; Simon Buček; Gregor Serša; Damijan Miklavčič
Journal:  Vaccines (Basel)       Date:  2020-01-27

Review 7.  Sintilimab: A Promising Anti-Tumor PD-1 Antibody.

Authors:  Lin Zhang; Wuqian Mai; Wenyang Jiang; Qing Geng
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

Review 8.  Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment.

Authors:  Giulio Giustarini; Andrea Pavesi; Giulia Adriani
Journal:  Front Bioeng Biotechnol       Date:  2021-06-02

Review 9.  The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.

Authors:  Katie Hudson; Neil Cross; Nicola Jordan-Mahy; Rebecca Leyland
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

Review 10.  Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy.

Authors:  Chiara Cremolini; Emanuela Vitale; Raffaella Rastaldo; Claudia Giachino
Journal:  Nanomaterials (Basel)       Date:  2021-03-08       Impact factor: 5.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.